The Effect of Adoptive Immunotherapy after Percutaneous Microwave Ablation in Recurrent Hepatocellular Carcinoma Patients with Hepatitis B: A Preliminary Study
To observe the influence of adoptive immunotherapy combination with percutaneous microwave ablation (PMWA) on peripheral blood examination, hepatic function examination and serum alpha fetoprotein (AFP) in recurrent hepatocellular carcinoma (HCC) patients with hepatitis B. Fourteen recurrent HCC patients with 31 lesions (D≤6.0cm, fewer than four tumors) were treated with radical PMWA and continuous four courses of adoptive immunotherapy, which were administrated at 1, 2, 3 and 4 months after PMWA, respectively. Under sonographic guidance, tumor lysate-pulsed DCs (1ml) were injected into bilateral groin lymph nodes at 9th day, while CTL (25ml) were injected into the abdominal cavity at 11th day and CIK (100ml) was infused intravenously at 14th day after hemospasis in one course of treatment, respectively. Peripheral blood examination, serum AFP and hepatic function were reviewed 1, 3, 6 months after adoptive immunotherapy. The number of white blood cell (WBC), lymphocyte (LYM), serum albumin (ALB) and cholinesterase (CHE) were detected increase significantly at 3 and 6 months after therapy compared to pre-therapy (p0.05). Platelet (PLT) was detected increased significantly at 6 months after therapy (p0.05) compared to pre-therapy. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were detected decreased significantly at 1, 3 and 6 months after therapy (p0.05). As to serum AFP, it was detected decreased gradually, while there was no difference during the follow-up (6-16 months). No severe adverse effects were observed. Adoptive immunotherapy prescribed soon after PMWA was safe and ameliorated the laboratory examination and the immunity status of recurrent HCC patients, which may improve the prognosis
